PharmHunterJen said:PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing.
Saving this. It is the first explanation that did not require me to already understand it. Taking it to my next appointment.
Clinical perspective, offered as context rather than as advice. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.
PeptideChemSF said:Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…
I am going to disagree with the direction of travel here. The thread has converged on the tidiest answer rather than the best-supported one, and those are not the same thing.
That is the short version; the long version is somebody else's post.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsOne concrete data point for the thread. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.